

10/509,396

* * * * * Welcome to STN International * * * * *
* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:00:31 ON 09 FEB 2006

=> file reg


=> Uploading C:\Program Files\Stnexp\Queries\10509396.str

L1 STRUCTURE UPLOADED

=> dis l1

L1-HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

L2 9 SEA SSS SAM L1

=> s l1 full

L3 331 SEA SSS FUL L1

=> file caplus

=> s l3

L4 10 L3

=> s l4 and pd<feb 2002

22507607 PD<FEB 2002
(PD<20020200)

L5 2 L4 AND PD<FEB 2002

=> dis l5 1-2 bib abs hitstr

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:549356 CAPLUS

DN 127:152950

TI Multiple unit effervescent dosage forms comprising proton pump inhibitor

IN Lundberg, Per Johan

PA Astra Aktiebolag, Swed.; Lundberg, Per Johan

SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9725030	A1	19970717	WO 1996-SE1738	19961220 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	SE 9600073	A	19970709	SE 1996-73	19960108 <--
	SE 512835	C2	20000522		
	CA 2214027	AA	19970717	CA 1996-2214027	19961220 <--
	AU 9713242	A1	19970801	AU 1997-13242	19961220 <--
	AU 712325	B2	19991104		
	BR 9607367	A	19971230	BR 1996-7367	19961220 <--
	EP 814783	A1	19980107	EP 1996-944727	19961220 <--
	EP 814783	B1	20031008		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1183716	A	19980603	CN 1996-193763	19961220 <--
	IL 121653	A1	20010808	IL 1996-121653	19961220 <--
	AT 251451	E	20031015	AT 1996-944727	19961220
	PT 814783	T	20040227	PT 1996-944727	19961220
	ES 2208775	T3	20040616	ES 1996-944727	19961220
	ZA 9610939	A	19970708	ZA 1996-10939	19961230 <--
	US 6132770	A	20001017	US 1997-793077	19970213 <--
	NO 9704051	A	19971015	NO 1997-4051	19970903 <--
	NO 319999	B1	20051010		
PRAI	SE 1996-73	A	19960108		
	WO 1996-SE1738	W	19961220		

OS MARPAT 127:152950


AB A new tabletted multiple unit effervescent dosage form containing an acid susceptible proton pump inhibitor in the form of the racemate, an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof, and effervescent tablet constituents are claimed (Markush structure given). The proton pump inhibitor is preferably omeprazole or an alkaline salt thereof, or S-omeprazole or an alkaline salt thereof. Pellets comprising non-pareil cores 400, lansoprazole 400, hydroxypropyl Me cellulose 80, sodium lauryl sulfate 3, and water 1360 g were prepared. The above pellets (100 g) were coated with a solution comprising hydroxypropyl Me cellulose 9, polyethylene glycol-6000 1, talc 18, 95% ethanol 250, and water 250 g. The above sub-coated pellets were enteric coated with a solution comprising hydroxypropyl Me cellulose phthalate 40, acetyltributyl citrate 8, cetanol 2, 95% ethanol 162, and acetone 378 g. The enteric-coated pellets were mixed with effervescent granules (preparation given) and compressed into tablets.

IT 193335-90-9


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multiple unit effervescent dosage forms comprising proton pump inhibitor)

RN 193335-90-9 CAPLUS


CN Ethanone, 2-(4-methoxy-3,5-dimethyl-2-pyridinyl)-1-(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1995:665761 CAPLUS
 DN 123:340706
 TI Synthesis and bioactivity of substituted adenines and adenosines
 AU Deng, H. F.; Jiang, Y. Z.; Zhao, Z. Z.
 CS Inst. Mater. Med., Chin. Acad. Med. Sci., Beijing, 100050, Peop. Rep. China
 SO Yaoxue Xuebao (1995), 30(5), 347-56
 CODEN: YHHPAL; ISSN: 0513-4870
 PB Chinese Academy of Medical Sciences, Institute of Materia Media
 DT Journal
 LA Chinese
 GI




AB Title compds. e.g., I (R = H, 2-pyridylmethyl, 3-methyl-2-pyridylmethyl, 3,5-dimethyl-2-pyridylmethyl, 3,5-dimethyl-4-methoxy-2-pyridylmethyl; R1 = PhCH₂, ribosyl, 2-pyridylmethyl, 3-methyl-2-pyridylmethyl, 3,5-dimethyl-2-pyridylmethyl, 3,5-dimethyl-4-methoxy-2-pyridylmethyl, 5-acetoxy-2-pyridylmethyl) were prepared using adenine and adenosine as starting materials. The structures of these compds. were identified with MS, ¹HNMR and UV spectra. All adenosine derivs. and some adenine derivs. synthesized were studied for adenosine receptor activity. I (R = 2-pyridylmethyl, R1 = ribosyl) was 33 times more active than adenosine.
 IT 170451-99-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and bioactivity of substituted adenines and adenosines)
 RN 170451-99-7 CAPLUS
 CN 9H-Purin-6-amine, 9-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]- (9CI)
 (CA INDEX NAME)



IT 170452-03-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and bioactivity of substituted adenines and adenosines)

RN 170452-03-6 CAPLUS

CN 3H-Purin-6-amine, 3-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]- (9CI)
(CA INDEX NAME)

=> s l4 not l5

L6 8 L4 NOT L5

=> dis l6 1-8 bib abs

L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:588961 CAPLUS

DN 143:115536

TI A preparation of (aminopyridinylethyl)imidazolopyridine derivatives,
useful as inducible NO-synthase inhibitorsIN Boer, Rainer; Marx, Degenhard; Ulrich, Wolf-Ruediger; Eltze, Manfred;
Nave, Ruediger; Strub, Andreas; Graedler, Ulrich; Fuchss, Thomas

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DT Patent



LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005061496	A1	20050707	WO 2004-EP52373	20040930
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRAI EP 2003-22040 A 20031001
 OS MARPAT 143:115536
 GI



AB The invention relates to a preparation of (aminopyridinylethyl)imidazolopyridine derivs. of formula I [wherein: R1 is H or alkyl; R2 is H, halogen, NH2, (cyclo)alkyl, or CF3, etc.; R3 is H, halogen, alkyl, or alkoxy R4 is alkyl or alkoxy], useful as antiinflammatory agents (inducible NO-synthase inhibitors). For instance, (aminopyridinylethyl)imidazolopyridine derivative II was prepared via condensation of 4-methyl-2-(tritylamino)picolinaldehyde with [3H-imidazo[4,5-b]pyridin-2-ylmethyl]triphenylphosphonium chloride and subsequent reduction of the obtained intermediate. The invention compds. were tested for NO-synthase activity [-logIC50(mol/L) values range from 6.58 to 8.15].

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:300447 CAPLUS

DN 142:373838



TI Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors

IN Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfred; Lehner, Martin; Ulrich, Wolf-Ruediger
 PA Altana Pharma A.-G., Germany
 SO PCT Int. Appl., 34 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030771	A1	20050407	WO 2004-EP52378	20040930
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	EP 2003-22053	A	20031001		
OS	MARPAT 142:373838				
GI					



AB Title compds. I [R1 = H, alkyl; R2 = H, alkyl; R3 = H, halo; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with N,N-dimethyl-4-bromobenzenesulfonamide. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and

revealed -logIC50 values in the range of 7.45 up to 7.86 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:300446 CAPLUS

DN 142:373837

TI Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors

IN Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfred; Lehner, Martin; Ulrich, Wolf-Ruediger

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DT Patent

LA English



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030770	A1	20050407	WO 2004-EP52377	20040930
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				

PRAI EP 2003-22046 A 20031001

OS MARPAT 142:373837

GI



AB Title compds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkoxyalkyl, hydroxyalkyl, etc.; R3 = alkyl, CF₃, completely or predominantly F-substituted alkoxy, etc.; R1 and R2 together = (un)saturated-, (un)substituted-nitrogen heterocycle; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible NO-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with 1-(4-bromo-benzene-sulfonyl)-4-methyl-piperazine. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC₅₀ values in the range of 6.51 up to 7.89 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:300445 CAPLUS

DN 142:373836

TI Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors

IN Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfred; Lehner, Martin; Marx, Degenhard; Ulrich, Wolf-Ruediger

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DT Patent



LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030769	A1	20050407	WO 2004-EP52376	20040930
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRAI EP 2003-22064 A 20031001
 OS MARPAT 142:373836
 GI





AB Title compds. I [R1 = alkoxy; A = alkylene; R2 = H, halo, alkyl, alkoxy; Het = (un)substituted monocyclic or fused 5-10 membered (un)saturated heteroaryl containing 1-3 heteroatoms selected from N, O, and S] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible NO-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with 2-furanylboronic acid. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values from 6.61 up to 7.61 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:300444 CAPLUS
 DN 142:373835
 TI Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors
 IN Boer, Rainer; Ulrich, Wolf-Ruediger; Eltze, Manfred; Marx, Degenhard; Graedler, Ulrich; Fuchss, Thomas
 PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030768	A1	20050407	WO 2004-EP52370	20040930
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	EP 2003-22042	A	20031001		
OS	MARPAT 142:373835				
GI					





AB Title compds. I [R1 = H, alkyl; R2 = H, halo, OH, etc.; R3 = H, halo, alkyl, alkoxy; R4 = alkyl; R5 = alkyl] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible NO-synthase inhibitors. Thus, e.g., II was prepared via Wittig reaction of triphenyl-{1-(3H-imidazo[4,5-b]pyridin-2-yl)-propyl}-phosphonium chloride (preparation given) with 4-methoxypyridine-2-carboxaldehyde and subsequent hydrogenation. The activity of II towards inducible NO-synthase was evaluated in an inhibition assay and revealed a -logIC50 value of 7.15 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:283463 CAPLUS
 DN 142:336389
 TI Preparation of novel heterocyclic compounds such as aminopurines, aminopyrrolopyrimidines, aminopyrazolopyrimidines and aminotriazolopyrimidines as HSP90-inhibitors
 IN Kasibhatla, Srinivas R.; Boehm, Marcus F.; Hong, Kevin D.; Biamonte, Marco A.; Shi, Jiandong; Le Brazidec, Jean-yves; Zhang, Lin; Hurst, David
 PA Conforma Therapeutics Corporation, USA
 SO PCT Int. Appl., 506 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005028434	A2	20050331	WO 2004-US31248	20040920
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005107343	A1	20050519	US 2004-945851	20040920
	US 2005113339	A1	20050526	US 2004-946628	20040920
	US 2005113340	A1	20050526	US 2004-946645	20040920
	US 2005119282	A1	20050602	US 2004-946637	20040920
PRAI	US 2003-504135P	P	20030918		
	US 2004-591467P	P	20040726		
OS	MARPAT 142:336389				
GI					



AB Novel heterocyclic compds. (shown as I; other Markush structures are given in the claims; variables defined below; e.g. [4-chloro-7-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amine (shown as II)) are described and demonstrated to have utility as Heat Shock

Protein 90 (HSP90) inhibiting agents. Method of synthesis and use of such compds. are also described. For I: X1 and X2 are N or -CR6; X3 is N or -CR3 (R3 is H, OH, a keto tautomer, -OR8, -CN, halogen, lower alkyl, or -C(O)R9); X4 is N or a group CR6 when X3 is N, and X4 is -CR6R7 when X3 is -CR3; R1 is halogen, -OR8, -SR8, or lower alkyl; R2 is -NR8R10; R4 is -(CH2)n- where n = 0-3, -C(O), -C(S), -SO2-, or -SO2N-; and R5 is alkyl, aryl, heteroaryl, alicyclic, heterocyclic, all optionally bi- or tricyclic, and (un)substituted with H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl, lower alicyclic, aralkyl, aryloxyalkyl, alkoxyalkyl, perhaloalkyl, perhaloalkyloxy, perhaloacyl, -N3, -SR8, -OR8, -CN, -CO2R9, -NO2, or -NR8R10; with provisos. Methods of preparation are claimed and >200 example prepns. are included. For example, II was prepared by alkylation of (4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amine with 2-chloromethyl-4-methoxy-3,5-dimethylpyridine hydrochloride.

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:777790 CAPLUS

DN 139:292156

TI Preparation of alkoxy pyridines as inducible nitric oxide synthase (iNOS) inhibitors

IN Boer, Rainer; Marx, Degenhard; Eltze, Manfred; Klein, Thomas; Nave, Ruediger; Graedler, Ulrich; Fuchss, Thomas; Barsig, Johannes; Ulrich, Wolf-Ruediger

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 52 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080607	A1	20031002	WO 2003-EP3076	20030325
	W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2480385	AA	20031002	CA 2003-2480385	20030325
	AU 2003226706	A1	20031008	AU 2003-226706	20030325
	EP 1490366	A1	20041229	EP 2003-744851	20030325
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008785	A	20050111	BR 2003-8785	20030325
	US 2005171125	A1	20050804	US 2003-509396	20030325
	JP 2005525388	T2	20050825	JP 2003-578361	20030325
	NO 2004004633	A	20041223	NO 2004-4633	20041027
PRAI	EP 2002-7049	A	20020327		
	WO 2003-EP3076	W	20030325		
OS	MARPAT 139:292156				
GI					



AB Title compds. I [wherein R¹ = alkoxy; A = alkylene; B = (un)substituted 3H-imidazo[4,5-b]pyridin-2-yl, 9H-purin-8-yl; their salts, N-oxides, and salts of the N-oxides] were prepared as inducible NO-synthase (iNOS) inhibitor for treatment of acute inflammatory diseases and chronic inflammatory diseases of peripheral organs and central nervous system (CNS). For example, II (m.p. = 116-117°) was prepared by cyclocondensation of Me 3-(4-methoxypyridin-2-yl)propionate (preparation given) with 2,3-diaminopyridine in the presence of polyphosphoric acid at 160° for 1 h. Selected invention compds. inhibited iNOS with -logIC₅₀ (M) in the range of 7.03-7.55. Thus, I and their pharmaceutical compns. are useful for treating acute inflammatory diseases, chronic inflammatory diseases of peripheral organs and CNS and cancer (no data).

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:539534 CAPLUS

DN 137:109285

TI Preparation of triazolo[4,5-d]pyrimidines as purinergic receptor antagonists

IN Gillespie, Roger John; Lerpiniere, Joanne; Gaur, Suneel; Bamford, Samantha Jayne; Stratton, Gemma Caroline; Leonardi, Stefania; Weiss, Scott Murray

PA Vernalis Research Limited, UK

SO PCT Int. Appl., 157 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055083	A1	20020718	WO 2002-GB91	20020110
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2433453 AA 20020718 CA 2002-2433453 20020110
 EP 1392312 A1 20040303 EP 2002-729452 20020110
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 CN 1496262 A 20040512 CN 2002-806303 20020110
 NZ 527248 A 20040528 NZ 2002-527248 20020110
 JP 2004517862 T2 20040617 JP 2002-555817 20020110
 BR 2002006559 A 20040622 BR 2002-6559 20020110
 ZA 2003005087 A 20040712 ZA 2003-5087 20020110
 NO 2003003146 A 20030909 NO 2003-3146 20030709
 US 2004097526 A1 20040520 US 2003-250942 20031008
 PRAI GB 2001-624 A 20010110
 WO 2002-GB91 W 20020110
 OS MARPAT 137:109285
 GI



AB The title compds. [I; R1 = H, alkyl, aryl, etc.; R2 = aryl attached via an unsatd. carbon; R3 = H, alkyl, COR5, CO2R7, CONR5R6, CONR4NR5R6, SO2R7; R4-R6 = H, alkyl, aryl; or NR5R6 = heterocyclyl; or where R4-R6 are in a CONR4NR5R6 group, R4 and R5 may be linked to form a heterocyclic group; R7 = alkyl, aryl], useful in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection, were prepared Thus, reacting 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (preparation given) with 2-fluorobenzyl bromide in the presence of NaH in DMF afforded 22% I [R1 = NH2; R2 = 2-furyl; R3 = 2-FC6H4CH2] which showed Ki of 3 nM against A2A receptor binding.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
35.01	202.60



FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-7.50	-7.50

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 13:02:55 ON 09 FEB 2006



chain nodes :

7 8 10 11

ring nodes :

1 2 3 4 5 6

chain bonds :

4-7 6-10 7-8 10-11

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

4-7 7-8 10-11

exact bonds :

6-10

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:CLASS 11:Atom

Generic attributes :

11:

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : 2 or more

Type of Ring System : Polycyclic

Element Count :

Node 11: Limited

N,N2